FDA Approves IDE study assessing Revita for weight maintenance after discontinuation of GLP-1
The FDA has approved a pivotal Investigational Device Exemption (IDE) to study the efficacy of Fractyl Health’s Revita system for...
FDA Approves IDE study assessing Revita for weight maintenance after discontinuation of GLP-1
Revita results in weight loss and sustained weight maintenance without weight regain at one year
Fractyl’s Revita DMR System commercially available in Germany
Fractyl Health reports latest Revita DMR outcomes for T2DM
Two-year Revita DMR outcomes show durability of procedure in diabetics
Fractyl gains US$100 million financing to expand clinical development programs for T2DM
Revita DMR granted FDA Breakthrough Device Designation for T2DM